Home
Clinical Trials
Partnerships
Contact Us
News & Resources
Careers
About Us
Management Team
Board of Directors
Scientific and Clinical Advisory Boards
Commercial Advisory Board
Our Focus
Infectious Disease
Oncology
Our Pipeline
Prophylactic
Therapeutic
Clinical Trials
Early/Expanded Access Policy
Our Science and Technology
Investors
Press Releases
Events and Presentations
Company Information
Stock Information
SEC Filings
Corporate Governance
About Us
Management Team
Board of Directors
Scientific and Clinical Advisory Boards
Commercial Advisory Board
Our Focus
Infectious Diseases
Oncology
Our Pipeline
Prophylactic
Therapeutic
Clinical Trials
Our Science and Technology
News and Resources
News
Posters
Videos
Publications
Investors
Press Releases
Company Information
Corporate Governance
Events and Presentations
SEC Filings
Stock Information
Careers
Partnerships
Contact Us
Search our website
Sci-B-Vac®
VBI Vaccines Announces Multiple Presentations at the Canadian Liver Meeting 2021
May 3rd, 2021
VBI Vaccines Announces U.S. FDA Acceptance of BLA Filing for VBI’s 3-Antigen Prophylactic Hepatitis B Vaccine
February 2nd, 2021
VBI Vaccines Announces Publication of Results from a Phase 4 Study of VBI’s Prophylactic 3-Antigen Hepatitis B Vaccine in Vaccine
January 15th, 2021
VBI Vaccines Announces European Medicines Agency Acceptance of Marketing Authorization Application (MAA) for 3-Antigen Prophylactic Hepatitis B Vaccine
December 23rd, 2020
VBI Vaccines Selects Syneos Health as Commercialization Partner for Prophylactic 3-Antigen Hepatitis B Vaccine
December 7th, 2020
VBI Vaccines to Discuss Hepatitis B Portfolio in Virtual Fireside Chat Hosted by Raymond James
December 2nd, 2020
VBI Vaccines Announces Submission of Biologics License Application to FDA for 3-Antigen Prophylactic Hepatitis B Vaccine
December 1st, 2020
VBI Vaccines Announces Submission of Marketing Authorization Application for 3-Antigen Prophylactic Hepatitis B Vaccine to the European Medicines Agency
November 23rd, 2020
VBI Vaccines Presents Phase 3 Sci-B-Vac® Data at The Liver Meeting® 2020
November 13th, 2020
VBI Vaccines Presents Phase 3 Sci-B-Vac® Data at ID Week 2020™
October 26th, 2020
VBI Vaccines to Present at the H.C. Wainwright Hepatitis B Virus (HBV) Mini-Conference
October 15th, 2020
VBI Vaccines Announces e-Poster Presentation at The Liver Meeting
®
2020
October 8th, 2020
VBI Vaccines to Present at Upcoming Scientific Conferences
September 24th, 2020
VBI Vaccines Presents Phase 3 Sci-B-Vac® Data at EASL 2020
August 31st, 2020
VBI Vaccines Announces Multiple Phase 3 Sci-B-Vac® Abstracts Accepted for Oral and Poster Presentations at EASL 2020
August 20th, 2020
VBI Vaccines Announces Second Pivotal Phase 3 Study of Sci-B-Vac® Meets Primary and Secondary Endpoints
January 9th, 2020
VBI Vaccines Announces Late-Breaker Poster Presentation at The Liver Meeting® 2019
October 22nd, 2019
VBI Vaccines Announces Late-Breaker Oral Presentation at IDWeek 2019™
October 2nd, 2019
VBI Vaccines Announces Positive Top-Line Results from PROTECT, a Pivotal Phase 3 Study of Sci-B-Vac®
June 17th, 2019
VBI Vaccines to Host Conference Call Tomorrow to Review PROTECT Phase 3 Clinical Data for Sci-B-Vac®
June 16th, 2019
Page 1 of 3
1
2
3
›
Sign-up for Our Distribution List to Receive the Latest News and Updates from VBI
Sign Up Now
